FI950697A - IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan - Google Patents

IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan Download PDF

Info

Publication number
FI950697A
FI950697A FI950697A FI950697A FI950697A FI 950697 A FI950697 A FI 950697A FI 950697 A FI950697 A FI 950697A FI 950697 A FI950697 A FI 950697A FI 950697 A FI950697 A FI 950697A
Authority
FI
Finland
Prior art keywords
antibodies
new uses
alone
optionally
manufacture
Prior art date
Application number
FI950697A
Other languages
English (en)
Swedish (sv)
Other versions
FI950697A0 (fi
Inventor
Robert Coffman
Vries Jan E De
Waal Malefyt Rene De
Fiona Powrie
Donna Rennick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI950697A0 publication Critical patent/FI950697A0/fi
Publication of FI950697A publication Critical patent/FI950697A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
FI950697A 1992-08-20 1995-02-16 IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan FI950697A (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93341992A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21
PCT/US1993/007646 WO1994004180A2 (en) 1992-08-20 1993-08-18 Novel uses of il-4 and/or il-10, and antibodies against the same

Publications (2)

Publication Number Publication Date
FI950697A0 FI950697A0 (fi) 1995-02-16
FI950697A true FI950697A (fi) 1995-04-07

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950697A FI950697A (fi) 1992-08-20 1995-02-16 IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan

Country Status (23)

Country Link
EP (2) EP0801951A3 (fi)
JP (1) JP3494647B2 (fi)
KR (1) KR0170037B1 (fi)
CN (1) CN1090204A (fi)
AT (1) ATE162947T1 (fi)
AU (1) AU680628B2 (fi)
CA (1) CA2142861C (fi)
CZ (1) CZ283488B6 (fi)
DE (1) DE69316921T2 (fi)
DK (1) DK0671933T3 (fi)
ES (1) ES2111769T3 (fi)
FI (1) FI950697A (fi)
GR (1) GR3026635T3 (fi)
HK (1) HK1004326A1 (fi)
HU (1) HU220103B (fi)
IL (1) IL106725A (fi)
MX (1) MX9305054A (fi)
MY (1) MY111402A (fi)
PL (1) PL307566A1 (fi)
RU (1) RU2120802C1 (fi)
SK (1) SK21195A3 (fi)
TW (1) TW243415B (fi)
WO (1) WO1994004180A2 (fi)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
RU2218348C2 (ru) * 1994-07-05 2003-12-10 Стено Рисерч Груп А/С Полипептид с il-10 подобными свойствами (варианты), конъюгат полипептида, фармацевтическая композиция, способ модуляции иммунного ответа у млекопитающего
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
EP0793504B1 (en) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (en) * 1995-08-01 1997-02-05 Institut Pasteur Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
EP0901375A1 (en) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea combination therapy
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
EP1176140B1 (en) 1999-02-10 2004-12-29 Mitsubishi Pharma Corporation Amide compounds and medicinal use thereof
AU4903801A (en) * 1999-12-03 2001-07-09 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
WO2007039586A1 (en) * 2005-10-03 2007-04-12 Actogenix Nv Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
NZ597098A (en) * 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2014172392A1 (en) * 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
DK3369435T3 (da) 2013-07-18 2019-11-25 Xalud Therapeutics Inc Sammensætning til behandling af inflammatorisk ledsygdom
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
JP3260368B2 (ja) * 1991-01-16 2002-02-25 シェリング・コーポレーション インターロイキン−１０による腫瘍性疾患の処置
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
MX9305054A (es) 1994-02-28
AU5010893A (en) 1994-03-15
DK0671933T3 (da) 1998-09-23
CZ283488B6 (cs) 1998-04-15
KR950702841A (ko) 1995-08-23
FI950697A0 (fi) 1995-02-16
HK1004326A1 (en) 1998-11-20
HUT70976A (en) 1995-11-28
RU2120802C1 (ru) 1998-10-27
IL106725A0 (en) 1993-12-08
WO1994004180A3 (en) 1994-06-09
CZ44195A3 (en) 1995-10-18
JPH08500362A (ja) 1996-01-16
RU95108330A (ru) 1996-11-27
EP0801951A3 (en) 1998-05-20
HU9500467D0 (en) 1995-04-28
DE69316921T2 (de) 1998-06-04
SK21195A3 (en) 1996-10-02
ES2111769T3 (es) 1998-03-16
HU220103B (hu) 2001-10-28
JP3494647B2 (ja) 2004-02-09
KR0170037B1 (ko) 1999-02-01
EP0671933A1 (en) 1995-09-20
CN1090204A (zh) 1994-08-03
CA2142861C (en) 2000-08-15
DE69316921D1 (de) 1998-03-12
ATE162947T1 (de) 1998-02-15
PL307566A1 (en) 1995-05-29
MY111402A (en) 2000-04-29
WO1994004180A2 (en) 1994-03-03
CA2142861A1 (en) 1994-03-03
AU680628B2 (en) 1997-08-07
EP0801951A2 (en) 1997-10-22
IL106725A (en) 2000-12-06
EP0671933B1 (en) 1998-02-04
TW243415B (fi) 1995-03-21
GR3026635T3 (en) 1998-07-31

Similar Documents

Publication Publication Date Title
FI950697A0 (fi) IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan
ATE163042T1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
ES2195970T3 (es) L-ribavirina y usos de la misma.
ES2176285T3 (es) Amidas y esteres de peptidos inhibidoras del cancer de seres humanos.
DE69033299D1 (de) Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften
DE69226622D1 (de) Lyophilisierte Bakterien enthaltende Diät- oder Arzneimittelnzusammenstellungen
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
ATE226947T1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
BR9916297A (pt) Material compósito esticável tendo pregas contìnuas
DE69416403D1 (de) Calanolide und aehnliche verbindungen diese enthaltende zusammensetzungen und ihre verwendung
DE69114184D1 (de) Harzzusammensetzung für Grundierung und Grundierungsmittel davon.
DE69329749D1 (de) Cycloolefincopolymer-zusammensetzung und deren herstellung
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69311463D1 (de) Pfropfpolymerteilchen, herstellung davon, und diese enthaltende zusammensetzung
BR9610206A (pt) Espiroxazinas fotocrônicas composições e artigos contendo as mesmas
ITMI932019A0 (it) Composizione farmaceutica antivirale contenente la 2-ammino 4,6-dicloropirimidina e metisoprinolo
DE69329271D1 (de) Sprengstoffzusammensetzung und deren herstellung
JO1770B1 (en) New formulations mainly composed of derivatives of sleepjestrol and the methods necessary to produce them
ATE82750T1 (de) Benzodioxol-derivate, diese enthaltende zusammensetzungen und deren verwendung zur herstellung von medikamenten.
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.

Legal Events

Date Code Title Description
BB Publication of examined application
FD Application lapsed